此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS) (SLEDAIS)

2026年6月24日 更新者:Zhongming Qiu、Xinqiao Hospital of Chongqing

Efficacy and Safety of Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial (SLEDAIS) involving 1,040 patients with acute ischemic stroke (AIS) who require inter-hospital transfer for potential endovascular therapy. The study aims to evaluate the efficacy and safety of sublingual Edaravone Dexborneol tablets administered in the ultra-early stage (within 6 hours of symptom onset) during the critical inter-hospital transfer window.

Patients will be randomly assigned in a 1:1 ratio to receive either sublingual Edaravone Dexborneol (a loading dose of 4 tablets initially, followed by 1 tablet twice daily for 13 days) or a matching placebo. The primary efficacy endpoint is the functional outcome assessed by the modified Rankin Scale (mRS) score at 90 days. The primary safety endpoint is the mortality rate at 90 days. This study seeks to provide high-quality evidence for neuroprotection during the transfer period, potentially improving functional recovery for stroke patients.

研究概览

研究类型

介入性

注册 (估计的)

1040

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400000
        • Xinqiao Hospital and The Second Affiliated Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Aged 18 to 80 years (inclusive).
  • Time from last known normal to arrival at the first hospital is within 6 hours.
  • Clinical and imaging diagnosis of acute ischemic stroke, with a Los Angeles Motor Scale (LAMS) score ≥ 4, or occlusion of the internal carotid artery, M1/M2 segment of the middle cerebral artery, V4 segment of the vertebral artery, or basilar artery confirmed by CTA/MRA at the first or target hospital.
  • ASPECTS score ≥ 6 on non-contrast head CT at the first hospital.
  • Clinically assessed as planned for immediate transfer to a target hospital for evaluation of endovascular therapy (final decision on whether to perform EVT is made by the neuro-interventionist at the target hospital based on imaging and clinical status).
  • Written informed consent signed by the patient or their legal representative.

Exclusion Criteria:

  • Allergy to contrast agents, nickel, titanium, or their alloys.
  • Known allergy to dexborneol, edaravone, or excipients.
  • Pre-stroke modified Rankin Scale (mRS) score ≥ 2.
  • Patients receiving intravenous thrombolysis alone.
  • Severe impairment of consciousness (e.g., GCS score < 8) or inability to cooperate with sublingual administration.
  • Severe hepatic or renal insufficiency (e.g., ALT/AST > 3 times the upper limit of normal, Cr > 2 times the upper limit of normal).
  • Estimated inter-hospital transfer time > 3 hours.
  • Pregnant or lactating women.
  • Arterial tortuosity and/or other arterial diseases where the thrombectomy device is expected to be unable to reach the target vessel.
  • Brain tumors with mass effect on imaging (except small meningiomas).
  • Currently participating in other drug clinical trials.
  • History of neurological or psychiatric diseases that hinder the assessment of neurological function.
  • Any late-stage disease with an expected life expectancy < 6 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂组
Matching placebo sublingual tablets identical in appearance, smell, and packaging to the active drug. Participants will receive a loading dose of 4 placebo tablets (each containing 60μg dexborneol, a trace amount solely for maintaining blinding with no expected therapeutic effect) within 10 minutes after randomization. From day 2 to day 14, participants will receive 1 placebo tablet twice daily. The placebo is designed to be indistinguishable from Edaravone Dexborneol tablets to maintain the double-blind design.
实验性的:Edaravone Dexborneol Group
Edaravone Dexborneol is a novel neuroprotective agent combining edaravone (a free radical scavenger) and dexborneol (an anti-inflammatory component) in a 5:1 ratio. In this study, participants in the experimental group will receive a loading dose of 4 sublingual tablets (each containing edaravone 30mg + dexborneol 6mg, total: edaravone 120mg + dexborneol 24mg) within 10 minutes after randomization during inter-hospital transfer. From day 2 to day 14, participants will receive 1 tablet twice daily. The sublingual formulation dissolves within 5 minutes, allowing rapid absorption through the sublingual venous plexus and bypassing hepatic first-pass effect. This high initial loading dose aims to rapidly establish therapeutic concentrations before endovascular therapy to provide neuroprotection during the critical transfer window.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Modified Rankin Scale (mRS) Score at 90 Days
大体时间:90 days
Functional outcome assessed by the modified Rankin Scale (mRS) at 90 days post-randomization. The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death), used to evaluate the degree of disability or dependence in daily activities.
90 days
Mortality Rate at 90 Days
大体时间:90 days
All-cause mortality rate within 90 days post-randomization.
90 days

次要结果测量

结果测量
措施说明
大体时间
Infarct Volume at 36 Hours
大体时间:36 hours
Infarct volume (ml) measured by non-contrast CT or MRI-DWI at 36 hours post-procedure.
36 hours
NIHSS Score at Discharge
大体时间:5-7 days or discharge
National Institutes of Health Stroke Scale (NIHSS) score assessed at 5-7 days or at hospital discharge, whichever comes first.
5-7 days or discharge
Proportion of Patients With mRS 0-1 at 90 Days
大体时间:90 days
Percentage of patients achieving excellent functional outcome (mRS score 0-1, indicating no symptoms or symptoms but no disability) at 90 days.
90 days
Proportion of Patients With mRS 0-2 at 90 Days
大体时间:90 days
Percentage of patients achieving functional independence (mRS score 0-2, indicating no to mild disability but able to care for self) at 90 days.
90 days
EQ-5D-5L Score at 90 Days
大体时间:90 days
Health-related quality of life assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire at 90 days.
90 days
Incidence of Symptomatic Intracranial Hemorrhage at 36 Hours
大体时间:36 hours
Incidence of symptomatic intracranial hemorrhage (sICH) assessed by Heidelberg criteria at 36 hours post-procedure.
36 hours
Incidence of Any Intracranial Hemorrhage at 36 Hours
大体时间:36 hours
Proportion of patients with any type of intracranial hemorrhage (including hemorrhagic infarction and parenchymal hematoma) at 36 hours.
36 hours
Incidence of Non-Intracranial Hemorrhage Complications
大体时间:90 days
Incidence of non-intracranial bleeding complications within 90 days, including gastrointestinal bleeding, urinary tract bleeding, oral or nasal mucosal bleeding, and subcutaneous hematoma.
90 days
Incidence of Non-Hemorrhagic Serious Adverse Events
大体时间:90 days
Incidence of non-hemorrhagic serious adverse events (SAEs) within 90 days.
90 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年6月24日

首先提交符合 QC 标准的

2026年6月24日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年6月24日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅